Compare YRD & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YRD | BCYC |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.8M | 438.4M |
| IPO Year | 2015 | 2019 |
| Metric | YRD | BCYC |
|---|---|---|
| Price | $4.51 | $7.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $18.73 |
| AVG Volume (30 Days) | 75.8K | ★ 329.4K |
| Earning Date | 11-25-2025 | 10-30-2025 |
| Dividend Yield | ★ 9.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.03 | N/A |
| Revenue | ★ $872,820,262.00 | $28,339,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.23 | ★ N/A |
| Revenue Growth | ★ 10.41 | N/A |
| 52 Week Low | $4.15 | $6.03 |
| 52 Week High | $8.74 | $21.50 |
| Indicator | YRD | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 36.66 | 50.66 |
| Support Level | $4.27 | $6.76 |
| Resistance Level | $4.64 | $7.83 |
| Average True Range (ATR) | 0.21 | 0.42 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 37.14 | 58.06 |
Yiren Digital Ltd is an AI-powered platform providing a comprehensive suite of financial and lifestyle services in China. Its mission is to elevate customers' financial well-being and enhance their quality of life by delivering digital financial services, tailor-made insurance solutions, and premium lifestyle services. The company supports clients at various growth stages, addressing financing needs arising from consumption and production activities, while aiming to augment the overall well-being and security of individuals, families, and businesses.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.